SINGAPORE, November 20, 2022 /PRNewswire/ — RVAC Medicines Pte. (RVAC), a messenger RNA (mRNA) technology platform company incubated by CBC Group, a dedicated healthcare asset management company headquartered in Singaporeand the Agency for Science, Technology and Research (A*STAR) today announced the signing of a Master Research Collaboration Agreement to jointly investigate and develop solutions to enhance manufacturing and mRNA analysis in Singapore.

Through this collaboration, RVAC and A*STAR will set up a joint laboratory based at A*STAR’s Bioprocessing Technology Institute (BTI) to develop a preclinical manufacturing platform, which will facilitate the generation of new raw materials and potentially of clinical quality for the development of mRNA vaccines and therapies targeting infectious diseases and other conditions with unmet needs.

Leveraging BTI’s deep expertise in processing technologies and analytical sciences for biotherapy and strong translational research in biomedical technologies across multiple A*STAR research institutes, this collaboration aims to enable innovators to the local ecosystem and global manufacturers to access the manufacturing platform to assist in preclinical asset development.

The collaboration utilizes RVAC’s extensive capabilities in mRNA, vaccine and drug delivery technologies, as well as knowledge and expertise in biopharmaceutical manufacturing, research and development (R&D), clinical development and commercialization. RVAC is developing mRNA-based vaccines targeting infectious diseases such as COVID-19, for which it launched a first-in-human vaccine clinical trial in September 2022. Other assets in the RVAC pipeline under development include vaccines targeting respiratory syncytial virus (RSV) and Clostridioides difficile (ICD). Since its foundation in June 2021RVAC has recruited a team of over 80 top scientists and experienced industry veterans, and established R&D centers in Boston, MAUnited States and ShanghaiPRC.

“Our collaboration with A*STAR brings together the innovative research and development experience of some of the world’s leading mRNA researchers,” said Dr. Sean Fu, general manager of the RVAC. “We are committed to providing the people, equipment and technology expertise, with the support of our R&D teams around the world, to this venture. Combined with the knowledge and experience of A*STAR, this partnership has the potential to further advance mRNA as a new class of drugs.”

Teacher Ng Huck HuiDeputy Managing Director, Biomedical Research Council, A*STAR, said: “Public-private partnerships are key enablers for translating science into impact. A*STAR’s multidisciplinary R&D capabilities in infectious diseases, artificial intelligence, protein analysis and engineering, combined with expertise, will advance the development of mRNA-based vaccines and therapies and will contribute to better health outcomes for Singapore and beyond.”

Fu Wei, Chairman and CEO of CBC Group, added, “The collaboration between RVAC and A*STAR is an important step in supporting the growth of innovative R&D that will ultimately lead to the development of vaccines and treatments. advanced for the benefit of a greater number of patients. with CBC’s mission to provide quality and accessible medical innovation through Asia and beyond. The collaboration will also improve the technological capacity of our ecosystem, which fits well with that of Singapore commitment to mission-driven, curiosity-driven R&D.”

About RVAC Medications

RVAC Medicines is an mRNA platform company headquartered in Singapore with R&D centers in Boston and Shanghai. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. The company is led by an experienced management team, supported by a world-renowned scientific advisory board. For more information, please visit www.rvacmed.com.

About the Radio-Canada Group

Based at SingaporeCBC Group (“CBC”) is from Asia the largest dedicated healthcare asset management company, focusing on platform building, buyout, credit/royalties and real estate in the healthcare space, including pharmaceutical and biotechnology services , medical technology and healthcare services. CBC is committed to creating lasting value by integrating global talent and innovation. Partnering with the world’s top entrepreneurs and scientists, its unique “investor-operator” approach has enabled leading healthcare companies to expand access to affordable medical care, catalyze innovation and improve the effectiveness in meeting unmet medical needs worldwide. Founded in 2014, CBC has built a world-class team of investment, industry and portfolio management professionals headquartered in Singapore with locations in Shanghai, beijing, hong kong, New York, Londonand Seoul. For more information, please visit www.cbridgecap.com. Join us on LinkedIn (Radio-Canada Group).

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is that of Singapore leading public sector R&D agency. Through open innovation, we collaborate with our partners in the public and private sectors for the benefit of the economy and society. As a science and technology organization, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and improves lives by improving societal outcomes in healthcare, urban living and sustainability. A*STAR plays a key role in developing scientific talent and leaders for the research community and industry at large. A*STAR’s R&D activities extend from biomedical sciences to physical sciences and engineering, with research entities mainly located in Biopolis and Fusionopolis. For current news, visit www.a-star.edu.sg.


Show original content:https://www.prnewswire.com/news-releases/rvac-medicines-and-astar-to-build-capabilities-for-mrna-production-in-singapore-301683406.html

SOURCE Radio-Canada Group

Donald E. Patel